Cell-Free DNA (cfDNA) Blood Collection Tube Market Growth Trends: Moderate Expansion with 13.4% CAGR Until 2029

 Get 30% Off All Market Studies With Code ONLINE30 — Anticipate Tariff Impacts, Market Disruptors, and Long-Term Growth Trends

 

 What Are the Key Factors Driving Cell-Free DNA (cfDNA) Blood Collection Tube Market Size and Growth?
 The cell-free DNA (cfDNA) blood collection tube market size has grown rapidly in recent years. It will grow from $1.17 billion in 2024 to $1.33 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to increasing prevalence of lifestyle-related disorders, rising focus on early genetic screening programs, growing acceptance of blood-based biomarker research, increasing number of diagnostic laboratories worldwide, and rising awareness of maternal and fetal health monitoring.
 
 The cell-free DNA (cfDNA) blood collection tube market size is expected to see rapid growth in the next few years. It will grow to $2.20 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to an increase in patient preference for minimally invasive procedures, a rise in the use of cfDNA in transplant monitoring, an increase in government initiatives supporting molecular diagnostics, an increase in the need for efficient sample transport and storage, and an increase in insurance coverage for molecular diagnostic tests. Major trends in the forecast period include advanced microfluidics-enabled blood collection tubes, innovation in sustainable and eco-friendly tube materials, integration with artificial intelligence for data-driven diagnostics, advancement in prenatal and oncology testing workflows, and integration with companion diagnostics for targeted therapies.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28160&type=smp
 
 What Are the Key Factors Contributing to Cell-Free DNA (cfDNA) Blood Collection Tube Market Growth?
 The increasing prevalence of respiratory disorders is expected to drive the growth of the cell-free DNA (cfDNA) blood collection tube market in the future. Respiratory disorders are medical conditions that affect the lungs and other parts of the respiratory system, impairing the ability to breathe efficiently and deliver oxygen to the blood or remove carbon dioxide from the body. The increasing prevalence of respiratory disorders is largely due to air pollution, which irritates the airways, reduces lung function, and increases the risk of conditions like asthma, bronchitis, and chronic obstructive pulmonary disease (COPD). Cell-free DNA (cfDNA) blood collection tubes are used in the management of respiratory disorders to detect genetic mutations, monitor disease progression, and assess treatment response through a simple blood test, thereby reducing the need for invasive lung biopsies. For instance, in December 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, between October 1 and November 30, 2024, an estimated 17,000 to 34,000 hospitalizations were caused by respiratory syncytial virus (RSV). Therefore, the increasing prevalence of respiratory disorders is driving the growth of the cell-free DNA (cfDNA) blood collection tube market.
 
 Surge In Cancer Driving The Growth Of The Market Due To Rising Unhealthy Lifestyle Habits
 
 The increasing incidence of cancer is expected to drive the growth in the cell-free DNA (cfDNA) blood collection tube market going forward. The incidence of cancer is increasing due to lifestyle factors such as poor diet, smoking, and lack of exercise. Cell-free DNA (cfDNA) blood collection tubes are used in cancer management to perform liquid biopsies, allowing detection of tumor-related genetic mutations, monitoring of disease progression, assessment of treatment response, and identification of resistance mutations through a simple blood test, reducing the need for invasive tissue biopsies. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, the number of cancer survivors in the United States is expected to reach 26 million by 2040 from 18.1 million in 2022. Therefore, the increasing incidence of cancer drives the growth of the cell-free DNA (cfDNA) blood collection tube market.
 
 Which Segment Holds the Largest Share in the Cell-Free DNA (cfDNA) Blood Collection Tube Market?
 The cell-free dna (cfDNA) blood collection tube market covered in this report is segmented as
 
 1) By Type: 5ml, 10ml
 2) By Sample Type: Plasma, Serum, Whole Blood
 3) By Application: In Vitro Diagnostics, Scientific Research
 4) By End-User: Diagnostic Laboratories, Hospitals Or Clinical Centers, Genetic Diagnostic Labs, Cancer Research Centers, Research And Development Institutions, Conventional Diagnostic Centers
 
 Subsegments:
 1) By 5 mL: Single Use Tube, Vacuum Blood Collection Tube, Gel Separator Tube
 2) By 10 mL: Double Draw Tube, High Volume Collection Tube, Anticoagulant Treated Tube
 
 What Are the Top Trends Expected to Shape the Cell-Free DNA (cfDNA) Blood Collection Tube Market by 2029?
 Major companies operating in the cell-free DNA (cfDNA) blood collection tube market are focusing on automation of cfDNA extraction to enhance workflow efficiency. Automation of cfDNA extraction refers to the use of advanced robotic instruments and standardized protocols to isolate cell-free DNA from blood samples with minimal manual intervention, improving efficiency, accuracy, and consistency while reducing turnaround time and human error. For instance, in September 2023, Yourgene Health plc, a UK-based molecular diagnostics company, launched the MagBench Automated DNA Extraction Instrument and Kit, offering a fast, simple, and cost-efficient bench-top robotic solution optimized for cell-free DNA extraction in non-invasive prenatal testing (NIPT) workflows. This launch aims to strengthen automation in NIPT workflows by delivering higher throughput, reproducibility, and reliability in cfDNA extraction while reducing hands-on time and operational costs. 
 
 Who Are the Emerging Players in the Cell-Free DNA (cfDNA) Blood Collection Tube Market?
 Major companies operating in the cell-free dna (cfdna) blood collection tube market are Roche Holding AG, Thermo Fisher Scientific Inc., Becton Dickinson (BD), Qiagen N.V., SARSTEDT AG & Co. KG, Guangzhou Improve Medical Technology, Streck Inc., DiaCarta Inc., Zymo Research Corporation, Biomatrica Inc., PreAnalytiX GmbH, Beijing Cowin Bioscience Co.Ltd., Norgen Biotek Corporation, Nonacus Limited, Guangdong Ardent Biomed Co. Ltd, MagBio Genomics Inc., VanGenes, BEAVER, Hebei Xinle Science & Technology Co. Ltd., Nasmed Diagnostics Pvt. Ltd.
 
 Get the full cell-free dna (cfdna) blood collection tube market report here:
 https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-blood-collection-tube-global-market-report
 
 What Are the Regional Opportunities for Investment in the Cell-Free DNA (cfDNA) Blood Collection Tube Market?
 North America was the largest region in the cell-free DNA (cfDNA) blood collection tube market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cell-free DNA (cfDNA) blood collection tube report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company